Literature DB >> 6092953

Lymphadenopathy-associated viral antibody in AIDS. Immune correlations and definition of a carrier state.

J Laurence, F Brun-Vezinet, S E Schutzer, C Rouzioux, D Klatzmann, F Barré-Sinoussi, J C Chermann, L Montagnier.   

Abstract

We investigated whether serologic evidence of lymphadenopathy-associated virus (LAV), an exogenous human T-cell lymphotropic and cytopathic retrovirus, correlated with the acquisition and transmission of the acquired immunodeficiency syndrome (AIDS). Serum from 17 of 25 patients with AIDS contained circulating IgG anti-LAV antibody (all of 5 adults with cancer and 6 of 12 adults and 6 of 8 children with opportunistic infections, with or without Kaposi's sarcoma). All of eight homosexual men with generalized lymphadenopathy or the AIDS-related complex and five homosexual men with AIDS prodromes who subsequently had AIDS were also seropositive. The anti-LAV antibody was not found in 99 of 100 healthy blood donors or in 23 patients with genetic immunodeficiencies, supporting the contention that LAV is unlikely to represent simply another opportunistic microorganism. An AIDS carrier state was indicated by the probable transfer of LAV from asymptomatic, immunologically competent mothers to their offspring. These data offer a basis for the hypotheses that LAV is a marker for AIDS, may be carried and transmitted in the absence of clinical findings or in vitro T-cell abnormalities, and is probably an etiologically important agent in AIDS and its prodromes.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6092953     DOI: 10.1056/NEJM198411153112001

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  18 in total

1.  Monocyte function in intravenous drug abusers with lymphadenopathy syndrome and in patients with acquired immunodeficiency syndrome: selective impairment of chemotaxis.

Authors:  G Poli; B Bottazzi; R Acero; L Bersani; V Rossi; M Introna; A Lazzarin; M Galli; A Mantovani
Journal:  Clin Exp Immunol       Date:  1985-10       Impact factor: 4.330

Review 2.  The natural history of human T lymphotropic virus-III infection: the cause of AIDS.

Authors:  M Melbye
Journal:  Br Med J (Clin Res Ed)       Date:  1986-01-04

3.  Detection of anti-HTLV-III/LAV antibody by enzyme-linked immunosorbent assay in high-risk individuals in Switzerland 1974-1985.

Authors:  J Stroun; I Graf; P C Frei
Journal:  Eur J Clin Microbiol       Date:  1985-12       Impact factor: 3.267

4.  Detection of antibodies to human T-lymphotropic virus type III by using a synthetic peptide of 21 amino acid residues corresponding to a highly antigenic segment of gp41 envelope protein.

Authors:  J J Wang; S Steel; R Wisniewolski; C Y Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

5.  Opportunistic infections in acquired immune deficiency syndrome result from synergistic defects of both the natural and adaptive components of cellular immunity.

Authors:  F P Siegal; C Lopez; P A Fitzgerald; K Shah; P Baron; I Z Leiderman; D Imperato; S Landesman
Journal:  J Clin Invest       Date:  1986-07       Impact factor: 14.808

6.  Immunoglobulin level in donor blood reactive for antibodies to human immunodeficiency virus.

Authors:  N Nath; C Wunderlich; F W Darr; D K Douglas; R Y Dodd
Journal:  J Clin Microbiol       Date:  1987-02       Impact factor: 5.948

7.  The Vancouver Lymphadenopathy-AIDS Study: 3. Relation of HTLV-III seropositivity, immune status and lymphadenopathy.

Authors:  W J Boyko; M T Schechter; E Jeffries; B Douglas; M Maynard; M O'Shaughnessy
Journal:  Can Med Assoc J       Date:  1985-07-01       Impact factor: 8.262

8.  Recombinant polypeptide from the endonuclease region of the acquired immune deficiency syndrome retrovirus polymerase (pol) gene detects serum antibodies in most infected individuals.

Authors:  K S Steimer; K W Higgins; M A Powers; J C Stephans; A Gyenes; C George-Nascimento; P A Luciw; P J Barr; R A Hallewell; R Sanchez-Pescador
Journal:  J Virol       Date:  1986-04       Impact factor: 5.103

9.  Epidemiological aspects of HTLV-III infection in Italy.

Authors:  P Rossi; M Carbonari; R Bonomo; M Galli; P E Manconi; B Scarpati; G Scano; C Gaetano; B Ensoli; F Aiuti
Journal:  Eur J Epidemiol       Date:  1985-12       Impact factor: 8.082

10.  Human immunodeficiency virus infection induces both polyclonal and virus-specific B cell activation.

Authors:  A Shirai; M Cosentino; S F Leitman-Klinman; D M Klinman
Journal:  J Clin Invest       Date:  1992-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.